Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Depreciation & Amortization (CF) of $626000.0 for Q1 2026, down 2.19% year-over-year from $640000.0 in Q1 2025, and down 5.72% quarter-over-quarter from $664000.0 in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $626000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 2.19% year-over-year to $626000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 1.77% YoY), while the FY2025 annual figure was $2.6 million, up 4.0% from the prior year.
- Depreciation & Amortization (CF) fell to $626000.0 in Q1 2026 per COGT's latest filing, from $664000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $675000.0 in Q4 2024 and bottomed at $69000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $519176.5 across 5 years, with a median of $606000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 666.67% — and 2026, when it decreased 2.19%.
- Cogent Biosciences' Depreciation & Amortization (CF) stood at $378000.0 in 2022, then surged by 66.14% to $628000.0 in 2023, then rose by 7.48% to $675000.0 in 2024, then dropped by 1.63% to $664000.0 in 2025, then fell by 5.72% to $626000.0 in 2026.
- Business Quant data shows COGT's Depreciation & Amortization (CF) at $626000.0 in Q1 2026, $664000.0 in Q4 2025, and $641000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | 741,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 741,000.00 |
| Mar 31, 2026 | 626,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Mar 31, 2025 | 640,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Mar 31, 2024 | 599,000.00 |
| Dec 31, 2023 | 628,000.00 |
| Sep 30, 2023 | 581,000.00 |
| Jun 30, 2023 | 562,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 378,000.00 |
| Sep 30, 2022 | 256,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | 48,000.00 |